Cleveland Clinic London: Redefining Neurology Care Through Expertise and Innovation

Cleveland Clinic London continues to set new benchmarks in neurological care, combining world-class expertise with cutting-edge technology to deliver exceptional outcomes for patients with complex brain, spine and peripheral nervous system conditions.

Our neurosciences institute offers comprehensive cutting-edge services, including advanced neurology, neurosurgery, and neurorehabilitation, supported by a dedicated neurosurgical theatre with intraoperative MRI and one of the largest private neuro-rehabilitation units in the country.

Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a devastating progressive disease – one without substantial disease-modifying treatment options. For a small number of ALS patients (5-10%), it is due to specific gene mutations. Historically, treatment options have been limited, leaving patients and families without much hope.

The MHRA granted approval for Tofersen on 22 July 2025, the first gene-targeted therapy for ALS. Tofersen is designed for adults with ALS caused by a SOD1 gene mutation, a rare, inherited form of motor neurone disease. It works by reducing the damaging activity of the abnormal gene and levels of neurofilament light chain (NfL), a biomarker of nerve damage. Cleveland Clinic London has treated its first patient with Tofersen, just weeks after the treatment was licensed. For the first time, a precision medicine approach has resulted in a meaningful advance in treatment for a specific group of patients with SOD1 ALS, a truly complex and devastating disease.

“For the small subset of patients with SOD1-related ALS, tofersen represents a genuine step change,” said Paul Jarman, Cleveland Clinic London Neurology Department Chairman. “This is the first therapy to directly target an underlying genetic cause of ALS. Precision medicines won’t cure ALS today, but for selected patients they can slow damage and help preserve independence for longer, and that is significant.”

Innovation is embedded in every aspect of our neurological services. Cleveland Clinic London leverages state-of-the-art treatment and diagnostic tools that accelerate recovery and improve functional outcomes.

In a landmark advancement for dementia care, Cleveland Clinic London now offers lecanemab and donanemab, the first disease-modifying treatments for Alzheimer’s disease. These therapies are effective for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Both drugs work by targeting amyloid plaques in the brain, slowing disease progression and functional decline rather than merely treating symptoms. The medications are delivered within a rigorous pathway to maximise safety and monitor closely for side effects.

As part of Cleveland Clinic’s global network, Cleveland Clinic London is committed to continuous innovation in neurology care. From pioneering minimally invasive techniques to expanding neurorehabilitation programs and introducing breakthrough therapies for Alzheimer’s and ALS, our focus is to deliver meaningful improvements in outcomes using evidence-based precision medicine for patients with complex and challenging neurological conditions.